In the case of sorafenib and imatinib, it was straightforward to identify the relevant targets of those drugs, because the targets were almost certain to be kinases. As these two drugs have a ...

Arguably the most prominent target for drug development these days is kinase-directed therapy. Almost daily, there are news reports, articles, patents, and clinical trials describing how kinase ...

The Chan Zuckerberg Initiative (CZI) announced four multi-year Exploratory Cell Networks grants for researchers exploring the frontiers of genomics, cell biology, and synthetic biology by developing ...

When it comes to finding therapeutic cancer targets, “mutated cancer genes are just the tip of the iceberg, but functional genomics can help uncover the much larger, submerged portion of the iceberg,” ...

To solve the kinome of Dictyostelium, Dr. Smith and her colleagues at Boston Biomedical utilized the power of bioinformatics, a cutting edge scientific technique which employs databases and computer ...

Safety interim analysis (SIA) of atractib: A phase 2 trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC ...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today introduced the SureSelect Kinome Target Enrichment Kit, enabling researchers to focus next-generation sequencing ...

Kinases have emerged in recent years as promising targets for therapeutic intervention, unsurprisingly, as mutations in kinase domains have been linked to an array of human disorders—most notably ...

SAN DIEGO -- Ambit Biosciences today announced significant enhancements to its KinomeScan™ profiling technology, the industry’s most comprehensive high-throughput system for screening small ...

Aptose Biosciences Inc. has bought over the worldwide rights to Hanmi Pharmaceutical Co. Ltd.’s myeloid kinome inhibitor in a deal worth up to $420 million. Seoul, South Korea-based Hanmi has granted ...